Cancer Research

Axelar Initiates Phase I/II Clinical Trial On Cancer Patients With The New Anti-Cancer Drug AXl1717

STOCKHOLM, June 17 /PRNewswire/-- Axelar AB today announced that the company recently has initiated a phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717, an insulin-like growth factor-1 (IGF-1) receptor inhibitor. The phase ...

Article - Anna Ohlden - Jun 17 2008 - 6:33am

Singapore Is One Of The Fastest Growing Bioclusters In Asia; Wave Of Investments In Drug Discovery And Translational Research

SAN DIEGO, June 17 /PRNewswire/--- Strong Government Support Continues to Draw Top Research Institutes, Talent, and Corporate Labs That Are Looking to Place Strategic Bets for the Future Singapore's investment of more than US$2.1 billion in the biome ...

Article - Anna Ohlden - Jun 17 2008 - 11:30am

ThromboGenics And BioInvent Announce A Strategic Alliance With Roche For TB-403, A Novel Anti-Cancer Antibody

LEUVEN, Belgium, LUND, Sweden and BASEL, Switzerland, June 18 /PRNewswire/-- ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (Nordic Exchange: BINV) announce that they have entered into a license agreement with Roche (SWX: ROG) fo ...

Article - Anna Ohlden - Jun 18 2008 - 12:33am

Nventa Develops Proprietary Vaccine Adjuvant

SAN DIEGO, June 18 /PRNewswire/--- Potent Adjuvant is a Toll-Like Receptor 3 (TLR3) Agonist Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that the company has developed a proprietary vaccine adjuvant, Poly IC-Poly Arginine (Poly-ICR), t ...

Article - Anna Ohlden - Jun 18 2008 - 6:33am

Canopus BioPharma Strengthens Its CB1400 Platform Technology For Mucositis And Oncology Treatments Through License Agreement Wit

LOS ANGELES, California, June 18 /PRNewswire/-- Canopus BioPharma, Inc. (OTC: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer and addiction, tod ...

Article - Anna Ohlden - Jun 18 2008 - 7:30am

Merck Serono And Bionomics Announce Multiple Sclerosis Development And Licensing Agreement

GENEVA, June 18 /PRNewswire/--- Bionomics and Merck Serono to Collaborate to Discover and Develop Novel, Oral Treatment for MS- Collaboration Based on Novel Compounds That Allow Selective Inhibition of The Immune Cells Which Cause Nerve Cell Damage in Pat ...

Article - Anna Ohlden - Jun 18 2008 - 7:30am

BIO 2008: Germany On Cutting Edge In Biomanufacturing

SAN DIEGO, California, June 18 /PRNewswire/-- Germany is on the cutting edge in biotechnology R&D and is a top player in large- and clinical-scale production. Companies located in Germany are poised to profit from the latest developments in biomanufac ...

Article - Anna Ohlden - Jun 18 2008 - 1:30pm

Vitamin D Linked To Colon Cancer Survival

Patients diagnosed with colon cancer who had abundant vitamin D in their blood were less likely to die during a follow-up period than those who were deficient in the vitamin, according to a new study by scientists at Dana-Farber Cancer Institute. The findi ...

Article - News Staff - Jun 18 2008 - 10:15pm

Radiation May Be Good For You, Says Study

Radiation is dangerous. In high doses it is certainly lethal and chronic exposure is linked to the development of cancer. That's why we have bomb shelters and canned food. But what if a short-term controlled exposure to a low dose of radiation were go ...

Article - News Staff - Jun 20 2008 - 1:36pm

Bavarian Nordic Reports Interim Data From Phase I/II Studies With Breast Cancer Vaccine

KVISTGÅRD, Denmark, June 19 /PRNewswire/-- Bavarian Nordic's cancer research unit, BN ImmunoTherapeutics, has completed an interim analysis of its first two clinical studies with MVA-BN(R)-HER2, a cancer vaccine immunotherapy for breast cancer patien ...

Article - Anna Ohlden - Jun 19 2008 - 2:33am